![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Halozyme Therapeutics to Acquire Antares Pharma for Nearly $1 Billion
Halozyme Therapeutics to Acquire Antares Pharma for Nearly $1 Billion
San Diego, Calif.-based Halozyme Therapeutics is purchasing Ewing, N.J.-headquartered Antares Pharma in a deal valued at approximately $960 million.
The acquisition will give Halozyme access to Antares’ Enhanze enzyme-based drug delivery technology and the company’s auto injector, which has potential uses for delivering a broad range of medications.
Antares has already developed several self-injection products, including the injectable testosterone drugs Xyosted (testosterone enanthate) and Tlando (testosterone undecanoate).
The transaction is expected to close in the first half of 2022.
Upcoming Events
-
18Jul
-
21Oct